Mary M. Horowitz, MD, MS

Publications

• Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

  (Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW.) Blood Adv. 2020 Feb 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 02/07/2020

• Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.

  (Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML.) Blood. 2020 Jan 09;135(2):97-107 PMID: 31738834 PMCID: PMC6952830 SCOPUS ID: 2-s2.0-85077761109 11/19/2019

• Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations.

  (Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D.) Biol Blood Marrow Transplant. 2019 Dec;25(12):2330-2337 PMID: 31002990 SCOPUS ID: 2-s2.0-85065760511 04/20/2019

• Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.

  (Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC.) Biol Blood Marrow Transplant. 2019 Nov;25(11):2160-2166 PMID: 31279752 PMCID: PMC6907401 SCOPUS ID: 2-s2.0-85069900077 07/08/2019

• FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?

  (Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ, Blood and Marrow Transplant Clinical Trials Network.) J Clin Oncol. 2019 Jul 01;37(19):1604-1607 PMID: 31034300 PMCID: PMC6804888 04/30/2019

• Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.

  (Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, Confer DL, Shaw BE, Switzer GE.) Biol Blood Marrow Transplant. 2019 05;25(5):955-964 PMID: 30605731 PMCID: PMC6511296 SCOPUS ID: 2-s2.0-85061429566 01/04/2019

• Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.

  (Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM.) Blood Adv. 2019 03 26;3(6):875-883 PMID: 30890544 PMCID: PMC6436017 SCOPUS ID: 2-s2.0-85072746485 03/21/2019

• Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

  (Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.) Lancet Haematol. 2019 Mar;6(3):e132-e143 PMID: 30824040 PMCID: PMC6503965 SCOPUS ID: 2-s2.0-85061920512 03/03/2019

• Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

  (Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A.) J Clin Oncol. 2019 03 01;37(7):589-597 PMID: 30653422 PMCID: PMC6553842 SCOPUS ID: 2-s2.0-85064136756 01/18/2019

• Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.

  (Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD.) JAMA Oncol. 2019 Dec 12 PMID: 31830234 PMCID: PMC6990739 SCOPUS ID: 2-s2.0-85076620276 12/13/2019

• Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.

  (Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M.) Bone Marrow Transplant. 2019 Oct 15 PMID: 31616063 SCOPUS ID: 2-s2.0-85074047416 10/17/2019

• Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.

  (Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M.) Bone Marrow Transplant. 2019 Sep 04 PMID: 31484992 SCOPUS ID: 2-s2.0-85073779919 09/06/2019